1 – 10 of 191
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Comorbidity and Mortality in Men and Women With Haemophilia in Three Nordic Countries–Comparisons to Matched Controls
- Contribution to journal › Article
-
Mark
Haemophilia B : an illustrative review of current challenges and opportunities
- Contribution to journal › Article
-
Mark
A plain language summary on indirectly comparing bleeding after valoctocogene roxaparvovec gene therapy to bleeding with emicizumab prophylaxis
- Contribution to journal › Article
-
Mark
Health-Related Quality of Life, Physical Activity and Joint Health in People With Severe Haemophilia A Receiving Emicizumab : Results From the Phase IV HemiNorth 2 Study
- Contribution to journal › Article
-
Mark
Evaluation of kidney function and damage in patients with hemophilia B—insights from the B-Natural study
- Contribution to journal › Article
- 2024
-
Mark
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B) : 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
- Contribution to journal › Article
-
Mark
Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
- Contribution to journal › Article
-
Mark
Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8) : a prospective, multicentre, open-label, randomised, phase 3a trial
- Contribution to journal › Article
-
Mark
Nonneutralizing antibodies in Nordic persons with moderate hemophilia A and B (the MoHem study)
- Contribution to journal › Article
-
Mark
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.
- Contribution to journal › Article
